50850-16-3

Usage

Uses

Due to the limited information available about the uses of 4,6-Dimethylpyridine-2,3-diamine, it is not possible to provide specific applications for 4,6-DIMETHYLPYRIDINE-2,3-DIAMINE. However, as a member of the Pyridines and derivatives group, it may have potential applications in various industries, such as pharmaceuticals, agrochemicals, or materials science. Further research and development are needed to explore its potential uses and establish its safety profile.

Upstream product

• 89791-76-4 2-amino-3-nitro-4,6-dimethyl-5-bromo-pyridine 
• 22934-23-2 2-amino-4,6-dimethyl-3-nitropyridine 
• 22934-22-1 3-Nitro-6-amino-2,4-dimethyl-pyridin 
• 5407-87-4 2-Amino-4,6-dimethylpyridine 
• 89856-44-0 2-amino-5-bromo-4,6-dimethylpyridine 

Downstream Products

• 133240-06-9 5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine 
• 401560-75-6 1,5,7-trimethyl-2-amidoimidazo[4,5-b]pyridine 
• 611180-20-2 4-methyl-N-(1,5,7-trimethyl-1H-imidazo[4,5-b]pyridin-2-yl)-benzenesulfonamide 
• 1197880-20-8 3-(4-bromobenzyl)-2-isopropyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine 
• 133052-12-7 2-Butyl-5,7-dimethyl-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazo[4,5-b]pyridine 
• 133051-72-6 2-Butyl-5,7-dimethyl-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazo[4,5-b]pyridine 
• 133240-47-8 5,7-Dimethyl-2-propyl-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazo[4,5-b]pyridine 
• 133240-46-7 L-158,809 
• 145004-87-1 5,7-Dimethyl-2-ethyl-3-[(2'-ethoxycarbonylamino sulfonylbiphenyl-4-yl)methyl]-3H-imidazo[4,5-b]pyridine 

Relevant academic research and scientific papers

SOMATOSTATIN MODULATORS AND USES THEREOF

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis

GPR4, a G-protein coupled receptor, functions as a proton sensor being activated by extracellular acidic pH and has been implicated in playing a key role in acidosis associated with a variety of inflammatory conditions. An orally active GPR4 antagonist 39c was developed, starting from a high throughput screening hit 1. The compound shows potent cellular activity and is efficacious in animal models of angiogenesis, inflammation and pain.

Syntheses of two potential food mutagens

The syntheses of the potential heterocyclic amine food mutagens 1,4,6-trimethyl-2-aminoimidazo[4,5-c]pyridine and 1,5,7-trimethyl-2 -aminoimidazo [4,5-b]pyridine are described.

PYRIDYL IMIDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF

Substituted pyridyl imidazole derivatives of formula (I) inhibit effectively the action of angiotensin II and have a superior anti-hypertensive activity. STR1

3N-Methylbiphenylsulfonylurea and -carbamate substituted imidazo[4,5-b]pyridines. Potent antagonists of the ANG II AT1 receptors

The synthesis and the SAR study of imidazo[4,5-b]pyridine biphenyl sulfonylureas and -carbamates as highly potent AT1-seIective ANG II receptor antagonists are described. Several members of this new class of antagonists efficiently inhibited the ANG II-induced presser response in pithed rats after iv and intraduodenal (id) administration.

Innovative approaches to the imidazo[4,5-b]pyridine ring system. Development of an efficient process for industrial-scale production of a key intermediate for potent angiotensin II receptor antagonists

Two syntheses of 2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine (3), an important intermediate for the synthesis of several potent angiotensin II antagonists, have been investigated. The first route involves conversion of 1,1-bis(methylthio)-2-nitroethene (17) to 2-ammo-4,6-dimethyl-3-nitropyridine (6); catalytic hydrogenation of 6 in propionic acid gave 3 in high yield. In the second synthesis, propionitrile is converted to imidate hydrochloride 15·HCl which is neutralised and reacted with aminoacetonitrile in the presence of acetylacetone to give 3 in 55% overall yield. The propionitrile route was scaled up to produce 3 in the pilot plant.

Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists

Substituted Imidazo-fused 6-membered heterocycles of structural formula: STR1 wherein A, B, C, and D are independently carbon atoms or nitrogen atoms are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.

Diaminopyridine compounds and methods of use

The present invention relates to compositions and method for inhibiting nonenzymatic cross-linking (protein aging) which contain diaminopyridines and derivates thereof. Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED PYRIDOIMIDAZOLYL RING

Substituted heterocycles attached through a methylene bridge to novel substituted phenyl derivatives of the Formula I are useful as angiotensin II antagonists. STR1

Angiotensin II antagonists incorporating a substituted thiophene or furan

There are disclosed substituted thiophene and furan derivatives of Formula I which are useful as angiotensin II antagonists. STR1